Resolve Therapeutics
Resolve Therapeutics is a pre-revenue, privately-held clinical-stage biotechnology company developing novel treatments for autoimmune diseases including systemic lupus erythematosus, lupus nephritis, and Sjögren's syndrome, leveraging the REJOIN-seq cell-free RNA platform through a 2026 collaboration with Institut Pasteur de Montevideo.
- Company typePrivate
- Founded2010
- HeadquartersKirkland, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Resolve Therapeutics does
Resolve Therapeutics is a privately-held, pre-revenue clinical-stage biotechnology company founded in 2010 and headquartered in Kirkland, Washington. The company is developing a novel approach to the treatment of Systemic Lupus Erythematosus (SLE) and related autoimmune conditions, including lupus nephritis and Sjögren's syndrome. Resolve operates with a lean team of 1-10 employees and has raised approximately $8.9 million across three disclosed financing tranches in 2011 and 2012, with no subsequent disclosed capital activity. The company's co-founder and CEO is James Posada. As of the available data, the company has no commercial products, no pricing structure, and no revenue-generating operations; its corporate website (resolvebio.com) remained in a "Launching Soon" pre-launch state, indicating no active commercial market presence.
The company's core technological differentiation is its access to the REJOIN-seq platform, developed at the Institut Pasteur de Montevideo. REJOIN-seq can restore and repair partially degraded cell-free RNA (cfRNA) that conventional sequencing methods fail to capture, enabling the identification of disease-related RNA molecules previously considered inaccessible. Resolve is leveraging this capability to identify upstream cfRNA triggers of inflammatory cascades in autoimmune disease. In April 2026, Resolve formalized a collaboration with Institut Pasteur de Montevideo to apply REJOIN-seq toward identifying cfRNA molecules driving inflammation in lupus and Sjögren's syndrome, with the stated aim of accelerating its clinical programs.
Resolve's business model is entirely R&D-oriented with no current commercial revenue mechanics. There are no disclosed pricing models, marketing channels, distribution channels, or customer logos. The company serves an ultimate end market of autoimmune disease patients, particularly those with SLE, lupus nephritis, and Sjögren's syndrome, but does not yet generate revenue from this population. The investor base is concentrated in early-stage life sciences investors Easton Capital, New Science Ventures, and Washington Research Foundation. The data explicitly notes that a similarly named entity, Resolve M Therapeutics (backed by Johnson & Johnson JJDC and General Inception, exited stealth January 2026 with a myeloid MS1 discovery platform), appears to be a distinct company and is not conflated with Resolve Therapeutics in this assessment.
Resolve Therapeutics firmographics
Firmographics- Name
- Resolve Therapeutics
- Website
- https://resolvebio.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Resolve Therapeutics is a pre-revenue, privately-held clinical-stage biotechnology company developing novel treatments for autoimmune diseases including systemic lupus erythematosus, lupus nephritis, and Sjögren's syndrome, leveraging the REJOIN-seq cell-free RNA platform through a 2026 collaboration with Institut Pasteur de Montevideo.
- Ownership category
- akta.pro rank
Resolve Therapeutics industry classification
Industry- Product category
- Autoimmune Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Resolve Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Kirkland
- HQ country
- United States
- HQ region
- North America
Markets served
Resolve Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Resolve Therapeutics product offering
Product offeringCore offering
Resolve Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for autoimmune diseases, with a primary focus on Systemic Lupus Erythematosus (SLE), lupus nephritis, and Sjögren's syndrome. The company leverages the REJOIN-seq technology through its collaboration with Institut Pasteur de Montevideo to identify cell-free RNA molecules that drive inflammation, enabling analysis of disease-related molecules previously considered lost by conventional sequencing methods.
Product overview
Resolve Therapeutics is a biotechnology company focused on autoimmune disease research. The company operates in collaboration with Institut Pasteur de Montevideo using the REJOIN-seq technology to identify cell-free RNA molecules that drive inflammation in diseases such as lupus and Sjögren's. The related entity Resolve M Therapeutics has unveiled a discovery platform leveraging myeloid cell state MS1 to engage pro-resolution immune responses for chronic inflammatory and autoimmune disorders.
Differentiator
Problem solved
Functional benefit
Products and services
- Autoimmune Disease Therapeutics Pipeline Pre-clinical and clinical-stage drug development programs targeting Systemic Lupus Erythematosus (SLE), lupus nephritis, and Sjögren's syndrome. The pipeline leverages the REJOIN-seq cfRNA restoration technology to identify upstream inflammatory triggers that drive autoimmune disease pathology.
Companies that use Resolve Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Resolve Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Resolve Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Institut Pasteur de MontevideocoreResolve Therapeutics and Institut Pasteur de Montevideo announced a collaboration to use the REJOIN-seq technology to identify cell-free RNA molecules that drive inflammation in autoimmune diseases such as lupus and Sjögren's. The technology, developed at Pasteur, can restore and repair partially degraded cfRNA that conventional sequencing methods cannot capture, enabling analysis of disease-related molecules previously lost. The partnership aims to advance understanding of the upstream triggers of inflammatory cascades in autoimmunity and potentially accelerate Resolve's clinical programs.
Recent moves4 records
Expansion highlights3 records
Resolve Therapeutics competitors and assessment
Company assessmentDirect peers
- Kymera Therapeutics: Kymera is a clinical-stage biotech developing targeted protein degraders for immunology and inflammation indications. Comparable as a small-cap autoimmune/inflammation biotech with platform-based discovery.
- AnaptysBio: AnaptysBio develops antibody-based therapeutics for autoimmune and inflammatory diseases. Comparable as a clinical-stage immunology biotech with platform technology and indication overlap in autoimmune disease.
- Cabaletta Bio: Cabaletta Bio is a clinical-stage biotech developing cell therapies for autoimmune diseases including lupus and Sjögren's syndrome. Comparable by indication, stage, and autoimmune therapeutic focus.
- Aurinia Pharmaceuticals: Aurinia Pharmaceuticals develops voclosporin (Lupkynis) for lupus nephritis, a directly overlapping indication with Resolve Therapeutics' autoimmune focus. Comparable clinical-stage-to-commercial biotech in lupus, with similar patient population and inflammatory mechanism.
- Annexon Biosciences: Annexon is a clinical-stage biotech developing complement-mediated therapies for autoimmune and inflammatory diseases. Comparable as a small-cap, mechanism-focused autoimmune biotech pursuing inflammatory drivers.
Broad incumbents
- Bristol Myers Squibb: BMS markets Benlysta (belimumab), the leading approved therapy for systemic lupus erythematosus. As a major incumbent in SLE, BMS represents the competitive and potential partnering benchmark for any lupus-focused biotech.
- Horizon Therapeutics (Amgen): Horizon (now part of Amgen) built a leading rare and autoimmune disease franchise, including products for Sjögren's-related conditions. Relevant incumbent comparator for autoimmune specialty indications.
- Novartis: Novartis has an extensive immunology pipeline including Cosentyx and active development in lupus and related autoimmune indications. Broad incumbent competitor with active inflammation franchise.
- Eli Lilly: Lilly has a major immunology portfolio including Olumiant (baricitinib) and is developing next-generation lupus and Sjögren's therapies. Represents a broad incumbent competitor and potential strategic partner for autoimmune assets.
Emerging players
- Resolve M Therapeutics: Recently emerged from stealth (January 2026) with Johnson & Johnson JJDC and General Inception backing, Resolve M operates in adjacent autoimmune/inflammation biology via a myeloid cell state MS1 platform. Comparable as a similarly-named, similarly-staged autoimmune biotech with a distinct but related platform approach.
Market position
Strengths4 records
Weaknesses1 record
Competitive moat1 record
Key risks5 records
Key highlights4 records
Customer concentration
Resolve Therapeutics social profiles
Digital presenceResolve Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Resolve Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Resolve Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Resolve Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Resolve Therapeutics
What does Resolve Therapeutics do?
Resolve Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for autoimmune diseases, with a primary focus on Systemic Lupus Erythematosus (SLE), lupus nephritis, and Sjögren's syndrome. The company leverages the REJOIN-seq technology through its collaboration with Institut Pasteur de Montevideo to identify cell-free RNA molecules that drive inflammation, enabling analysis of disease-related molecules previously considered lost by conventional sequencing methods.
When was Resolve Therapeutics founded?
Resolve Therapeutics was founded in 2010. It employs 1 to 10 people.
Where is Resolve Therapeutics based?
Resolve Therapeutics is headquartered in Kirkland, United States, in the North America region.
Who are Resolve Therapeutics's main competitors?
Direct peers on record are Kymera Therapeutics, AnaptysBio, Cabaletta Bio, Aurinia Pharmaceuticals and Annexon Biosciences. Broad incumbents are Bristol Myers Squibb, Horizon Therapeutics (Amgen), Novartis and Eli Lilly. Resolve M Therapeutics is listed as an emerging player.
Does Resolve Therapeutics have an API?
No public API is recorded for Resolve Therapeutics.
What industry is Resolve Therapeutics in?
Resolve Therapeutics's product category is Autoimmune Disease Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714.